Skip to content
WeighLab
Provider review

Mevo Health Review: Price, Pros & Cons

By The WeighLab Bench, Tools & Data Desk

Mevo Health is a direct-pay telemedicine platform selling compounded semaglutide ('as low as $199') and tirzepatide ('as low as $259') under named Medical Director Dr. David Wasef, head of the Mevo Provider Network.

In this review

Compounded drugs are not FDA-approved. Treatment requires a clinician's assessment. Understand compounded GLP-1 treatment.

Check Mevo Health prices Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. See our disclosure.

Prices at a glance

Semaglutide
From $199/moCompounded injection; dose and plan term require confirmation
Tirzepatide
From $259/moCompounded injection; dose and plan term require confirmation
Coverage
Coverage not published
Brand-name
Not confirmed

Semaglutide · estimated annual cost

$2,388

Tirzepatide · estimated annual cost

$3,108

Who Mevo Health may suit

Patients who want a named physician-led network and can confirm their medication price and plan term before paying.

Where the value is

  • Named, board-certified Medical Director (Dr. David Wasef) heading a stated provider network
  • LegitScript verification badge displayed
  • Publishes the FDA compounded-medication disclaimer verbatim
  • Cancel-anytime language ('cancel before the next billing cycle') suggests no long lock-in beyond the billing period chosen

The tradeoffs

  • The $199/$259 floors are not tied to a specific dose or plan length on the public page
  • Plans include monthly, quarterly and six-month options; confirm the full charge
  • The dispensing pharmacy is not identified before ordering
  • State eligibility must be confirmed during intake

Mevo Health's prices and plan lengths

Mevo Health sells two medications, both weekly injections: compounded semaglutide from $199 a month and compounded tirzepatide from $259 a month. Those are "as low as" prices. Plans come in monthly, quarterly and six-month lengths, and Mevo doesn't say on its site which plan length or dose each low price belongs to. Ask before you pay what the plan you're choosing costs per month, whether it's billed upfront, and whether the price changes as your dose goes up.

Mevo is direct pay, so you don't need insurance, and its terms say federal and state health programs such as Medicare won't cover it. Treatment includes ongoing access to your provider team for questions and dose changes, plus a member community for accountability.

Considering Mevo Health?

Check the plan total, billing period and cancellation terms before you enroll. A clinician decides whether treatment is appropriate.

The doctors behind it

Mevo names the physicians who prescribe. The provider network is led by Dr. David Wasef, a board-certified internal medicine physician. Three others are listed with their specialties: Dr. Frank Suppa in family medicine, Dr. Andrew Sakla in internal medicine and Dr. Constantin Chikando in emergency medicine.

Treatment works in four steps:

  1. Fill in a secure online health questionnaire covering your history, current medications and goals.
  2. A Mevo network physician reviews it and may ask for more information before deciding.
  3. If you're a good candidate, the physician writes a personalized plan.
  4. Follow-up oversight continues, with dose adjustments as needed.

Pharmacy, states and canceling

Medications are prepared by licensed 503A U.S. compounding pharmacies, which mix each prescription for a named patient. Mevo shows logos of the pharmacies it may use, and says the one filling your order depends on where you live and what your physician decides. It doesn't tell you in advance which one.

Mevo doesn't list the states it serves. Its terms say some services are limited to certain states and that you must live in one where Mevo operates, so confirm yours during intake.

You can cancel before your next billing cycle, by email to the care team. Mevo doesn't publish a refund policy, so ask what happens to a quarterly or six-month payment if you stop early.

Compounded semaglutide and tirzepatide are not FDA-approved.

The Index scorecard

Mevo Health scored on our six Cost-Efficiency Index factors. See the methodology.

Normalized Cost/Month55/100
Price Transparency78/100
Nationwide Access24/100
Formulation Options66/100
Clinical Oversight73/100
Contract Flexibility63/100

The bottom line

Mevo Health is a direct-pay telemedicine platform selling compounded semaglutide ('as low as $199') and tirzepatide ('as low as $259') under named Medical Director Dr. David Wasef, head of the Mevo Provider Network.

Compare the total cost of other GLP-1 programs and alternatives to Mevo Health before deciding. A clinician should help you choose the right treatment.

Other programs to compare with Mevo Health

These are partners: we may earn a commission if you sign up, at no cost to you.

  • Direct MedsPartner

    Semaglutide modeled $249/mo · Tirzepatide modeled $299/mo

    Direct Meds sells semaglutide and tirzepatide both as a sublingual and as an injection, every product priced in the open, from $249 a month on a plan that bills against a 90-day supply.

  • Belle HealthPartner

    Semaglutide modeled $109/mo · Tirzepatide modeled $179/mo

    Belle offers compounded GLP-1 subscriptions with flat dose pricing, licensed clinician care and several named pharmacy partners.

  • WillowPartner

    Semaglutide modeled $299/mo · Tirzepatide modeled $399/mo

    Willow is a direct-to-consumer telehealth provider offering compounded semaglutide and tirzepatide in both injectable and oral-tablet form at identical prices per format.

Compare with other providers

The providers whose Cost-Efficiency Index scores sit closest to Mevo Health's. See the alternatives to Mevo Health.

Explore more provider reviews

Pricing, states and verification reflect Mevo Health's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Mevo Health's site. Not medical advice; see our disclosure.

← Back to the value leaderboard